Optiver Holding
CYTK icon

Optiver Holding’s Cytokinetics CYTK Stock Holding History

Optiver Holding’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2K Buy
660
+475
+257% +$34.1K ﹤0.01% 1133
2026
Q1 		$12.2K Sell
185
-537
-74% -$34.1K ﹤0.01% 1182
2025
Q4 		$45.9K Sell
722
-133
-16% -$8.27K ﹤0.01% 914
2025
Q3 		$47K Sell
855
-211
-20% -$8.69K ﹤0.01% 793
2025
Q2 		$35.2K Buy
1,066
+244
+30% +$8.49K ﹤0.01% 693
2025
Q1 		$33K Buy
+822
New +$37.8K ﹤0.01% 588

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's CYTK Position: Q2 2026 in Review

Optiver Holding increased its Cytokinetics (CYTK) stake by 257% in Q2 2026, buying an estimated $34.1K and bringing the position to 660 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1133.

Optiver Holding first reported a position in CYTK in Q1 2025 and has held it in 6 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Optiver Holding held 660 shares of Cytokinetics worth $56.2K as of Q2 2026.
  • Optiver Holding bought 475 Cytokinetics shares in Q2 2026, an estimated $34.1K.
  • Cytokinetics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1133 holding.
  • Optiver Holding first reported a position in Cytokinetics in Q1 2025 and has held it in 6 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.